Ipsen to buy Canbex Therapeutics
Canbex Therapeutics Ltd. said Tuesday it granted Ipsen the right to buy 100 percent of Canbex shares once Canbex completes the Phase IIa study of its lead candidate for the treatment of spasticity in people with multiple sclerosis, known as VSN16R. Ipsen will pay 6 million euros (US$6.8 million) upfront for the option to buy Canbex, the statement said Canbex investors include Wellcome Trust, MS Ventures, Fast Forward LLC, UCL Business Plc and Esperante.
24 February 2015•6 mins read
